Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast [0.03%]
早期乳腺癌患者应放弃哨淋巴结活检吗？且慢！
Quyen D Chu,Prakash Peddi
Quyen D Chu
As major advances are made in the management of early breast cancer, the role of sentinel lymph node biopsy (SLNBx) has been called into question. However, before abandoning SLNBx, a critical appraisal of its role should be done because we ...
Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice [0.03%]
regorafenib治疗法国转移性结直肠癌患者的有效性、安全性和成本分析
Fabien Calcagno,Sabrina Lenoble,Zaher Lakkis et al.
Fabien Calcagno et al.
Background: Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved ...
Fertility Risk Assessment and Preservation in Male and Female Prepubertal and Adolescent Cancer Patients [0.03%]
儿童和青少年恶性肿瘤患者生育力风险评估与保存
Nikolaos Zavras,Charalampos Siristatidis,Argyris Siatelis et al.
Nikolaos Zavras et al.
Cancer represents the second cause of death in prepubertal children and adolescents, although it is currently associated with an overall survival rate of 80%-85%. The annual incidence rate is 186.6 per 1 million children and adolescents age...
Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies [0.03%]
可切除的胆管癌：辅助治疗策略的作用综述
E Una Cidon
E Una Cidon
Cholangiocarcinoma is a very heterogeneous and rare group of neoplasms originating from the perihilar, intra-, or extrahepatic bile duct epithelium. It represents only 3% of gastrointestinal cancers, although their incidence is increasing a...
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? [0.03%]
抗血管生成疗法治疗结直肠癌应答标志物研究进展及未来方向
E Una Cidon,P Alonso,B Masters
E Una Cidon
Despite advances in the treatment of colorectal cancer (CRC), it remains the second most common cause of cancer-related death in the Western world. Angiogenesis is a complex process that involves the formation of new blood vessels from pree...
Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study [0.03%]
每周一次紫杉醇与每三周一次紫杉醇治疗复发性铂耐药上皮性卵巢癌和腹膜癌的III期临床试验
Mohammed A Osman,Mohammad S Elkady,Khalid E Nasr
Mohammed A Osman
Introduction: Treatment of recurrent platinum-resistant ovarian and peritoneal cancers represents a therapeutic challenge. The aim of this Phase III prospective study was to compare the survival benefits, objective respon...
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting [0.03%]
三阴性乳腺癌中的肿瘤浸润淋巴细胞：免疫治疗的未来方向
Paula García-Teijido,María Luque Cabal,Ignacio Peláez Fernández et al.
Paula García-Teijido et al.
Triple negative breast cancer (TNBC) is a highly heterogeneous tumor. There is increasing evidence of the role of tumor lymphocytic immune infiltrates in this subtype of breast cancer. Robust levels of tumor infiltrating lymphocytes (TILs) ...
Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy [0.03%]
癌症治疗引起的神经病变的分子生物学和临床缓解措施研究
Gerald M Higa,Corbin Sypult
Gerald M Higa
Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. De...
Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations [0.03%]
浆液性卵巢癌的激素受体：预后、发病机制和治疗考虑因素
Ioannis A Voutsadakis
Ioannis A Voutsadakis
A few breakthroughs have been accomplished for the treatment of ovarian cancer, the most deadly gynecologic carcinoma, in the current era of targeted oncologic treatment. The estrogen receptor was the first target of such treatments with th...
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It [0.03%]
HER2扩增型乳腺癌患者曲妥珠单抗耐药机制及应对策略
María Luque-Cabal,Paula García-Teijido,Yolanda Fernández-Pérez et al.
María Luque-Cabal et al.
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common ...